10x Genomics CEO plans $2.2M stock sale

10x Genomics, Inc. (TXG) is the issuer in a notice that Serge Saxonov, its Director and CEO, intends to sell up to 35,486 shares of Class A common stock under Rule 144 through J.P.

Rhea-AI Filing Summary

10x Genomics, Inc. (TXG) is the issuer in a notice that Serge Saxonov, its Director and CEO, intends to sell up to 35,486 shares of Class A common stock under Rule 144 through J.P. Morgan Securities LLC. The proposed sale has an aggregate market value of $2,206,653.92, with 120,212,296 shares of Class A common stock reported as outstanding. The shares to be sold were acquired via 10,486 RSUs vesting on August 21, 2026 as compensation and 25,000 shares from an option exercise on April 1, 2019 for cash. Over the prior three months, Saxonov sold 30,000 shares of Class A common stock on June 22, 2026 for proceeds of $1,033,268.67.

Key Figures

Shares proposed to be sold under Rule 144: 35,486 shares of Class A Common Aggregate market value of proposed sale: $2,206,653.92 Shares of Class A Common outstanding: 120,212,296 shares +5 more

8 metrics

Shares proposed to be sold under Rule 144 35,486 shares of Class A Common Number of shares in the planned sale through J.P. Morgan Securities LLC

Aggregate market value of proposed sale $2,206,653.92 Aggregate market value of the 35,486 shares to be sold

Shares of Class A Common outstanding 120,212,296 shares Reported outstanding Class A Common shares of 10x Genomics, Inc.

RSU vesting shares to be sold 10,486 shares Shares acquired via RSU vesting on August 21, 2026 as compensation

Option exercise shares to be sold 25,000 shares Shares acquired via option exercise on April 1, 2019 for cash

Recent shares sold 30,000 shares Shares of Class A Common sold on June 22, 2026 in the prior three months

Proceeds from recent sale $1,033,268.67 Total proceeds from 30,000 shares sold on June 22, 2026

Approximate date of proposed sale August 26, 2026 Approximate date listed for the Rule 144 sale on Nasdaq

Key Terms

Rule 144, RSU Vesting, Option Exercise, aggregate market value, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

RSU Vesting financial

"Class A Common | 08/21/2026 | RSU Vesting | Issuer"

RSU vesting is the process by which restricted stock units — a promise by a company to give shares to an employee — become actual, owned shares over time or when certain goals are met. Investors care because vested shares can dilute existing ownership when issued, and the timing of vesting affects when employees can sell shares, which can influence share supply, insider selling patterns, and company incentives.

Option Exercise financial

"Class A Common | 04/01/2019 | Option Exercise | Issuer"

aggregate market value financial

"Class A Common | JP Morgan Securities LLC ... | 35486 | 2206653.92"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

compensation financial

"10486 | 08/21/2026 | Compensation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for TXG disclose about Serge Saxonov's planned stock sale?

The filing states that Serge Saxonov plans to sell up to 35,486 shares of 10x Genomics Class A common stock under Rule 144 through J.P. Morgan Securities LLC, with an aggregate market value of $2,206,653.92 based on the values reported.

How many TXG shares has Serge Saxonov sold recently according to this Form 144?

The notice reports that Serge Saxonov sold 30,000 shares of 10x Genomics Class A common stock on June 22, 2026, for total proceeds of $1,033,268.67 during the prior three months.

How were the TXG shares to be sold by Serge Saxonov acquired?

The filing indicates 10,486 shares were acquired via RSU vesting on August 21, 2026 as compensation, and 25,000 shares were acquired through an option exercise on April 1, 2019 for cash.

What is the reported market value of the TXG shares covered by this Form 144?

For the proposed sale of 35,486 shares of 10x Genomics Class A common stock, the filing lists an aggregate market value of $2,206,653.92 under Rule 144.

How many TXG Class A shares are reported as outstanding in this Form 144?

The notice reports that there are 120,212,296 shares of 10x Genomics Class A common stock outstanding in connection with the proposed Rule 144 sale disclosure.

Which broker is handling Serge Saxonov's proposed TXG share sale?

The filing identifies J.P. Morgan Securities LLC, located at 270 Park Avenue, New York, as the broker-dealer for the proposed Rule 144 sale of 10x Genomics Class A common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 06:10 PM EDT Accepted by SEC EDGAR 08/26/2026 - 06:09 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001786720
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	10X Genomics, Inc.
SEC File Number	001-39035
Address of Issuer	6230 Stoneridge Mall Road Pleasanton CALIFORNIA 94588
Phone	925-401-7300
Name of Person for Whose Account the Securities are To Be Sold	Serge Saxonov
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director, CEO

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common	JP Morgan Securities LLC 270 Park Avenue, 10th Floor New York NY 10017	35486	2206653.92	120212296	08/26/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common	08/21/2026	RSU Vesting	Issuer			10486	08/21/2026	Compensation
Class A Common	04/01/2019	Option Exercise	Issuer			25000	04/01/2019	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Serge Saxonov Care of TXG Genomics Inc 6230 Stoneridge Mall Road Pleasanton CA 94588	Class A Common	06/22/2026	30000	1033268.67

144: Remarks and Signature

Remarks
Date of Notice	08/26/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Serge Saxonov
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)